

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/077340 A1

- (51) International Patent Classification⁷: **A61K 9/16**, 9/22, 9/52, 31/135, 31/137, A61P 25/24, 1/00
- (21) International Application Number:
PCT/US2005/002215
- (22) International Filing Date: 25 January 2005 (25.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/542,384 6 February 2004 (06.02.2004) US
- (71) Applicant (for all designated States except US): **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DIORIO, Christopher, Richard** [US/US]; 16 Booth Drive, Campbell, NY 10916 (US). **SHAH, Syed, M.** [US/US]; 1 Ora Court Drive, East Hanover, NJ 07936 (US). **FAWZI, Mahdi, B.** [US/US]; 1 Ddukes Court, Morristown, NJ 07960 (US).
- (74) Agents: **KODROFF, Cathy, A.** et al.; Howson and Howson, 321 Norristown Road, Suite 200, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/077340 A1

(54) Title: MULTIPARTICULATE O-DESMETHYLVENLAFAXINE SALTS AND USES THEREOF

(57) Abstract: A multiparticulate O-desmethylvenlafaxine (ODV) succinate or formate is described. Methods of treating depression and reducing the gastrointestinal side-effects of ODV are also described.

MULTIPARTICULATE O-DESMETHYLVENLAFAXINE SALTS AND USES THEREOF

BACKGROUND OF THE APPLICATION

O-desmethylvenlafaxine (ODV), the major metabolite of venlafaxine, selectively blocks the reuptake of serotonin and norepinephrine. Klamerus, K. J. et al., "Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite", *J. Clin. Pharmacol.* **32**:716-724 (1992). O-desmethyl-venlafaxine, chemically named 1-[2-(dimethylamino)-1-(4-phenol)ethyl]-cyclohexanol, was exemplified as a fumarate salt in U.S. Pat. No. 4,535,186. However, the fumarate salt of O-desmethyl-venlafaxine has unsuitable physicochemical and permeability characteristics. O-desmethyl-venlafaxine is also exemplified as a free base in International Patent Publication No. WO 00/32555.

The succinate form of ODV has been described [US Patent 6,673,838]. The succinate monohydrate form of ODV has been incorporated into an extended release hydro-gel tablet, which reduces adverse effects such as nausea, vomiting, diarrhea, and abdominal pain. Formulations describing the use of hydroxypropyl methylcellulose (HPMC) as the hydrogel matrix have been described [WO 02/064543 A2].

However, the effects of the hydrogel formulation have been observed to be variable when the ODV hydrogel tablet is given with food.

20 SUMMARY OF THE INVENTION

The present invention provides a multiparticulate form of ODV that reduces undesirable characteristics associated with ODV and the hydrogel formulation thereof. These ODV multiparticulates are composed of ODV succinate, ODV formate, or combinations thereof.

25 Advantageously, this formulation also allows more convenient dosing to patients who have difficulty swallowing solid foods.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a multiparticulate formulation of an O-desmethylvenlafaxine (ODV) that contains a multiparticulate form of ODV succinate (DVS), ODV formate (DVF), or a combination thereof.

5 The use of a multiparticulate formulation facilitates dosing to pediatric patients, geriatric patients, and patients who have trouble swallowing, by dispersing the spheroids in a suspending liquid or sprinkling /dispersing in a low pH liquid like applesauce, prior to administration. The smaller size of the multiparticulates, in a capsule or pouch or any other container, also allows dosing through nasogastric or
10 gastrostomy tube.

Suitably, the multiparticulate ODV is a spheroid, bead or pellet, which is generally in the range of about 0.6 mm to about 1 mm in size. However, this may vary in size, without departing from the present invention.

The multiparticulate ODV of the invention are composed, at a minimum, of a
15 core composed of DVS, DVF or a combination thereof, and one or more diluents, binders, fillers, glidants, anti-adherents, a pH adjuster and/or an adjuvant.

DVS is prepared as described in US Patent 6,673,838, which is incorporated by reference herein. The formate salt of ODV (DVF), described in published US Patent Application PublN No. US 2003/0236309, which is incorporated by reference
20 herein, can be prepared using similar techniques by substitution of the appropriate salt. The multiparticulate core contains about 3% w/w to about 70% w/w DVS and/or DVF. In other embodiments, the DVS or DVF can range from about 5% w/w to about 60% w/w, from about 10 % w/w to about 50% w/w, from about 20 % w/w to about 40% w/w, or from about 25% w/w to about 35% w/w, about 30 % w/w to about
25 45% w/w, or about 32% to about 44% w/w, based upon 100% weight of the uncoated dosage form.

Suitably, the total amount of diluent, binders, fillers, glidants, anti-adherents, and adjuvants present in the core is an amount of about 30% w/w to about 97% w/w of the multiparticulate core. For example, when present, a binder, diluent and/or filler
30 can each be present in an amount of about 15 % w/w to about 80 % w/w, or about 20% w/w to about 70 % w/w, or about 25% w/w to about 45% w/w, or about 30%

w/w to about 42 % w/w of the uncoated dosage form. The total amount of a pH adjuster in the formulation can range from about 0.1% w/w to about 10% w/w of the core, or about 1% w/w to about 8% w/w, or about 3% w/w to about 7% w/w. However, these percentages can be adjusted as needed or desired by one of skill in the art.

The binder may be selected from among known binders, including, e.g., cellulose, and povidone, among others. In one embodiment, the binder is selected from among microcrystalline cellulose, crospovidone, and mixtures thereof.

Suitable pH adjusters include, e.g., sodium carbonate, sodium bicarbonate, potassium carbonate, lithium carbonate, among others. Still other suitable components will be readily apparent to one of skill in the art.

In one embodiment, the DVS and/or DVF is in a sustained release formulation which contains rate-controlling components. Typically, such rate controlling components are rate controlling polymers selected from among hydrophilic polymers and inert plasticized polymers. Suitable rate controlling hydrophilic polymers include, without limitation, polyvinyl alcohol (PVA), hypomellose and mixtures thereof. Examples of suitable insoluble or inert "plastic" polymers include, without limitation, one or more polymethacrylates (i.e., Eudragit® polymer). Other suitable rate-controlling polymer materials include, e.g., hydroxyalkyl celluloses, poly(ethylene) oxides, alkyl celluloses, carboxymethyl celluloses, hydrophilic cellulose derivatives, and polyethylene glycol.

In one embodiment, an ODV multiparticulate of the invention contains about 5% w/w to about 75% w/w microcrystalline cellulose (MCC), about 10 % w/w to about 70% w/w MCC, about 20% w/w to about 60 % w/w, or about 30 % w/w to about 50% w/w, based on the weight of the uncoated dosage unit.

In one embodiment, the multiparticulate DVS or DVF-containing core is uncoated. The multiparticulates can be placed into a suitable capsule shell or compressed into tablets, using techniques know to those of skill in the art. Suitably, the results capsule shell or compressed tablets contain 10 mg to 400 mg of ODV.

In other embodiments, the multiparticulate ODV contain one or more coatings over the core. In still other embodiments, the multiparticulate consists of a pellet core and non-functional seal coating and a functional second coating.

In one embodiment, an initial seal coat can be applied directly to the core.

5 Although the components of this seal coat can be modified by one of skill in the art, the seal coat may be selected from among suitable polymers such as hydroxypropyl methylcellulose (HPMC), ethylcellulose, polyvinyl alcohol, and combinations thereof, optionally containing plasticizers and other desirable components. A particularly suitable seal coat contains HPMC. For example, a suitable seal coat can be applied as
10 a HPMC solution at a concentration of about 3% w/w to 25% w/w, and preferably 5% w/w to about 7.5% w/w. Upon drying, under suitable conditions, the initial seal coat is in the range of about 1 % w/w to about 3% w/w, or about 2% w/w, of the uncoated multiparticulate. In another embodiment, a commercially available seal coat containing HPMC, among other inert components, is utilized. One such
15 commercially available seal coat is Opadry® Clear (Colorcon, Inc.).

Optionally, the multiparticulates can contain a further coating layer over the initial seal coat, if present, or directly to the uncoated multiparticulate ODV core, to provide a delay release formulation. These formulations may also lower the incidence of the side effects, including nausea, emesis, and irritable bowel syndrome. Without
20 wishing to be bound by theory, it is believed that these side-effects are avoided by bypassing release in the upper GI tract and providing release in the lower GI tract.

An enteric coat (rate-controlling film) may be applied to the multiparticulates and may include, but is not limited to polymethacrylates, hypomellose, and ethylcellulose, or a combination thereof. The modified release multiparticulate
25 formulation can contain from about 3 % w/w to about 70% w/w of DVS, DVF, or a combination thereof, and from about 5% w/w to about 75% w/w microcrystalline cellulose, based on the weight of an uncoated dosage form.

In one embodiment, the enteric coat contains a product which is a copolymer of methacrylic acid and methacrylates, such as the commercially available Eudragit®
30 L 30 K55 (Röhm GmbH & Co. KG). Suitably, this enteric coat is applied such that it coats the multiparticulate in an amount of about 15 to 45 % w/w, or about 20 % w/w

to about 30% w/w, or about 25% w/w to 30% w/w of the uncoated or initially-coated multiparticulate. In one embodiment, the enteric coat is composed of a Eudragit® L30D-55 copolymer (Röhm GmbH & Co. KG), talc, triethyl citrate, and water. More particularly, the enteric coating may contain about 30% w/w of a 30 wt% dispersion
5 of Eudragit® L 30 D55 coating; about 15% w/w talc, about 3% triethyl citrate; a pH adjuster such as sodium hydroxide and water.

In another embodiment, the enteric coat contains an ethylcellulose-based product, such as the commercially available Surelease® aqueous ethylcellulose dispersion (25% solids) product (Colorcon, Inc.). In one embodiment, a solution of
10 Surelease® dispersion of about 3% w/w to about 25% w/w, and preferably about 3% to about 7%, or about 5% w/w, is applied to the multiparticulate. Upon drying under suitable conditions, the enteric coat is in the range of about 2% to about 5%, or about 3% to about 4% w/w of the uncoated or initially-coated multiparticulate.

In one embodiment, the enteric-coated multiparticulate is further coated with a
15 final seal coat. Suitably, this final seal coat is composed of HPMC and water, upon drying, is less than about 1 wt% of the total, coated multiparticulate.

II. Method of Producing Multiparticulate Formulations of Invention

The multiparticulate formulations of the invention can be prepared using the
20 techniques described herein, as well as methods known to those of skill in the art.

In one embodiment, the uncoated ODV multiparticulates are prepared as follows. The dry components, including, at least the DVS and/or DVF and the binder are dry blended in a suitable mixer, e.g., a Hobart mixer. Optionally, the HPMC and a pH adjuster may be included in this step. Subsequently, the liquid components, e.g.,
25 the surfactant and water, are mixed in to afford a granulated product. The granulation is then extruded and spheronized through a suitable device (e.g., a Nica extruder/spheronizer) and the resulting spheroids are dried, sifted, and optionally blended prior to storage.

In another embodiment, the uncoated ODV multiparticulates are prepared as
30 follows. The DVS and binder are combined and granulated with water in a planetary mixer, such as a Hobart mixer. Then using the Nica® System the resulting wet mass

is extruded through a 1 mm screen. The extrudates are then transferred to a spheronizer and spun until spherical pellets are obtained (approximately 2 to 3 minutes). The wet pellets are then dried in an Aeromatic Strea™ fluid bed dryer to a moisture level of 2% to 5%. The dried pellets are then passed through a mesh screen
5 to remove larger oversize pellets.

Optionally, an initial seal coat can be applied to the uncoated multiparticulates. For example, an initial seal coat can be applied on a fluid bed coater, e.g., by spraying. In one embodiment, an Aeromatic Strea™ fluid bed apparatus is fitted with a Wurster column and bottom spray nozzle system.
10 Approximately 200 grams of the dried pellet cores are charged into the unit. The Opadry® Clear seal coat is applied with an inlet temperature of approximately 50°C to 60°C, a coating solution spray rate of 5 to 10 grams/minute, atomization pressure of 1 to 2 bar. The desired product temperature is 35°C to 45°C, and preferably 38°C to 43°C.

15 The enteric coat can be applied directly to the uncoated spheroid core, i.e., the uncoated multiparticulate, or may be applied over an initial seal coat. The enteric coat, as described above, is typically applied on a fluid bed coater. In one embodiment, Surelease® aqueous ethylcellulose dispersion (25% solids) is applied in a similar fashion as the seal coat. After the ethylcellulose coat is applied, the pellets
20 are dried for an additional 5 to 10 minutes. They are then removed and screened through a mesh screen to remove agglomerates and oversize particles.

In one embodiment, a final seal coat is applied over the enteric coat and, optionally, talc is utilized as a final step prior to filling the multiparticulates into a suitable packaging unit.
25

III. Formulations/Kits/Methods of delivery

In another embodiment, the present invention provides products containing the ODV multiparticulates of the invention.

In one embodiment, the ODV multiparticulates are packaged for use by the
30 patient or his caregiver. For example, the multiparticulates can be packaged in a foil

or other suitable package and is suitable for mixing into a food product (e.g., applesauce or the like) or into a drink for consumption by the patient.

In another embodiment, the ODV multiparticulates are suspended in a physiologically compatible suspending liquid. For oral liquid pharmaceutical
5 compositions, pharmaceutical carriers and excipients can include, but are not limited to water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like.

In yet another embodiment, the ODV multiparticulates are filled in capsules, caplets or the like for oral delivery.

10 In another embodiment, the present invention provides for the use of multiparticulate formulations of the invention in the preparation of medicaments, including but not limited to medicaments useful in the treatment of depression, gastrointestinal side-effects of venlafaxine in a subject undergoing treatment therewith, and irritable bowel syndrome.

15 In another embodiment, the present invention provides for the use of multiparticulate formulations of the invention in the preparation of medicaments for delivery to a pediatric or geriatric patient.

In other embodiments, the present invention provides for the use of multiparticulate formulations of the invention in the preparation of dosing units,
20 including but not limited to dosing units for oral, transdermal, or mucosal administration.

Also encompassed by the invention are pharmaceutical packs and kits comprising a container, such as a foil package or other suitable container, having a formulation of the invention in unit dosage form.

25 In still a further embodiment, the invention provides method of treating a subject in need thereof by administering an effective dose of the ODV multiparticulates of the invention. The formulations of the invention are useful in treatment of depression, anxiety, panic disorder, generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder, fibromyalgia,
30 agorophobia, attention deficit disorder, obsessive compulsory disorder, social anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de

la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, chronic fatigue syndrome, urinary incontinence, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's disease, and epilepsy. These formulations are also useful for enhancing cognition or treating
5 cognitive impairment in a patient, cessation of smoking or other tobacco uses in a patient, treating hypothalamic amenorrhea in a depressed or non-depressed human female, lowering the incidence of nausea, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, or trismus resulting from the oral administration of O-desmethylvenlafaxine succinate.

10 Suitably, the multiparticulate ODV of the invention can reduce the gastrointestinal side-effects of venlafaxine in a subject undergoing treatment therewith comprising administering to the patient a formulation of the invention.

An effective amount of the multiparticulate of the invention is an amount sufficient to prevent, inhibit, or alleviate one or more symptoms of the
15 aforementioned conditions. The dosage amount useful to treat, prevent, inhibit or alleviate each of the aforementioned conditions will vary with the severity of the condition to be treated and the route of administration. The dose, and dose frequency will also vary according to age, body weight, response and past medical history of the individual human patient. In generally the recommended daily dose range for the
20 conditions described herein lie within the range of 10 mg to about 1000 mg DVS or DVF per day and more preferably within the range of about 15 mg to about 350 mg/day and still more preferably from about 15 mg to about 140 mg/day. In other embodiments of the invention the dosage will range from about 30 mg to about 90 mg/day. Dosage is described in terms of the free base and is adjusted accordingly for
25 the succinate salt. In managing the patient, is generally preferred that the therapy be initiated at a lower dose and increased if necessary. Dosages for non-human patients can be adjusted accordingly by one skilled in the art.

A DVS or DVF multiparticulate may also be provided in combination with other active agents including, e.g., venlafaxine. The dosage of venlafaxine is
30 preferably about 75 mg to about 350 mg/day and more preferably about 75 mg to about 225 mg/day. Still more preferably the dosage of venlafaxine is about 75 mg to

about 150 mg/day. The ratio of DVS and/or DVF multiparticulate will vary from patient to patient depending upon a patient's response rate, but generally will be at least 6:1 ODV salt to venlafaxine. Venlafaxine or another active agent delivered in a regimen with the multiparticulate of the invention may be formulated together with
5 the multiparticulate of the invention, or delivered separately.

Any suitable route of administration can be employed for providing the patient with an effective amount of ODV multiparticulate. For example, oral, mucosal (e.g. nasal, sublingual, buccal, rectal or vaginal), parental (e.g. intravenous or intramuscular), transdermal, and subcutaneous routes can be employed. Preferred
10 routes of administration include oral, transdermal and mucosal.

Multiparticulate DVS and/or DVF can be combined with a pharmaceutical carrier or excipient (e.g., pharmaceutically acceptable carriers and excipients) according to conventional pharmaceutical compounding technique to form a pharmaceutical composition or dosage form. Suitable pharmaceutically acceptable
15 carriers and excipients include, but are not limited to, those described in Remington's, The Science and Practice of Pharmacy, (Gennaro, A. R., ed., 19th edition, 1995, Mack Pub. Co.) which is herein incorporated by reference. The phrase "pharmaceutically acceptable" refers to additives or compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric
20 upset, dizziness and the like, when administered to an animal, such as a mammal (e.g., a human).

Oral solid pharmaceutical compositions may include, but are not limited to starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders and disintegrating agents. The pharmaceutical composition and dosage form
25 may also include venlafaxine or a salt thereof as discussed above.

The following examples illustrate exemplary dosage forms of the multiparticulate ODV of the invention, and the use thereof. These examples are not a limitation on the present invention.

EXAMPLE 1 – Multiparticulate ODV Succinate (DVS) Formulations

Multiparticulate Dosage Form A

5	<u>Ingredient</u>	<u>mg/300 mg</u>	<u>%w/w</u>
	DVS	151.75 (100 as ODV free base)	50.58
	<u>Microcrystalline cellulose</u>	<u>148.25</u>	<u>49.42</u>
	Total	300	100.00

10 Multiparticulate Dosage Form B

	<u>Ingredient</u>	<u>mg/300 mg</u>	<u>%w/w</u>
	DVS	151.75 (100 as ODV free base)	50.58
	Hypomellose	75.0	25.00
15	<u>Microcrystalline cellulose</u>	<u>73.25</u>	<u>24.42</u>
	Total	300	100.00

EXAMPLE 2 - Multiparticulate ODV Formate (DVF) Formulations

Dosage Form A for DVF

20

	<u>Ingredient</u>	<u>mg/300 mg</u>	<u>%w/w</u>
	DVF	118.3 (100 as ODV free base)	39.43
	<u>Microcrystalline cellulose</u>	<u>181.7</u>	<u>60.57</u>
	Total	300	100.00

Multiparticulate Dosage Form B for DVF

	Ingredient	mg/300 mg	%w/w
	DVF	118.3 (100 as ODV free base)	39.43
	Hypomellose	90.85	30.28
5	<u>Microcrystalline cellulose</u>	<u>90.85</u>	<u>30.28</u>
	Total	300	100.00

The multiparticulate formulation is anticipated to provide a sustained, therapeutically effective plasma level over at least a 16 to 20 hour period. Similar to the hypomellose tablet model [See, US Patent 6,673,838 and US 6,274,171], the time to peak plasma levels (Tmax) is expected to be generally three to ten hours, more preferably 6 to 9 hours. The Tmax is critical for the reduction in adverse effects such as nausea and vomiting by bypassing the receptors in the upper GI tract, which are responsible for these adverse effects. Moreover, the increases in the Cmax (peak concentration) and AUC (total area under the concentration-time curve) observed with the hypomellose table in the fed state will not be observed in the multiparticulate formulation due to quicker elimination from the stomach accompanied by a smaller quantity of dissolved drug passing from the stomach to the upper GI tract. The multiparticulate formulation will also demonstrate a reduction of patient-to-patient variability as well as dose to dose variability due to the fact that they can easily pass through the pylorus whereas a hypomellose table may have difficulty, especially after some tablet swelling has occurred. The modified release pellet formula also demonstrates a reduction of nausea, vomiting, diarrhea, abdominal pain, headache, vaso-vaginal malaise, and/or trisumus.

25

EXAMPLE 3 - Preparation of Coated Desvenlafaxine succinate (DVS)

Multiparticulates Formulation

Ingredient	Grams/2000 grams	% wt/wt
DVS	1400.0	70.0
Microcrystalline cellulose	600.0	30.0
Water	Qs	qs

5 The manufacturing of the multiparticulate core was as follows. The desvenlafaxine succinate (DVS) is combined with microcrystalline cellulose and granulated with water in a planetary mixer. Then using the Nica® system the resulting wet mass is extruded through a 1 mm screen. The DVS extrudates are then transferred to the spheronizer and spun at approximately 700 rpm until spherical
10 pellets are obtained (2-3 minutes).

The wet pellets are then dried in an Aeromatic Strea™ fluid bed dryer to a moisture level of 2% to 5%. The dried pellets are passed through an 18 mesh screen to remove larger oversize pellets. The pellets are now ready for the coating process.

15 Coating

Seal Coat

Ingredient	Grams/500 grams	% wt/wt
Opadry® Clear (HPMC)	25.0	5
Water	475.0	95.0

The Aeromatic Strea™ fluid bed apparatus is fitted with a Wurster column and bottom spray nozzle system. Approximately 200 grams of the dried pellet cores
20 are charged into the unit. The Opadry® seal coat is applied with an inlet temperature of approximately 60°C, a coating solution spray rate of 5-10 grams/minute, atomization pressure of 1-2 bar. The desired product temperature is 38°C-43°C.

After approximately a 2% weight gain of the seal coat is achieved the ethylcellulose coat can be applied.

Ethylcellulose coat

Ingredient	Grams/500 grams	% wt/wt
Surelease® (aqueous ethylcellulose dispersion 25% solids)	25.0	5
Water	475.0	95.0

5

The ethylcellulose is applied in a similar fashion as the seal coat to a weight gain of 3-4%. After the ethylcellulose coat is applied, the pellets are dried for an additional 5-10 minutes. They are removed and screened through an 18 mesh screen to remove agglomerates and oversize particles.

10

Dissolution Testing of Coated DVS Multiparticulates

The resulting coated multiparticulates were tested in-vitro for the DVS-233 release rate. Pellets containing DVS multiparticulates having an active amount equivalent to 150 mg of desvenlafaxine were tested using USP Apparatus I, baskets at 15 100 rpm. The dissolution media was 0.9% NaCl at 37°C.

The results demonstrate that the uncoated DVS multiparticulate product provided immediate release (< 1 hour), which was sustained for at least 24 hours. The coated DVS multiparticulate product had delayed release [< 50% release after 2 hours, < 70% release after 4 hours, and < 90% release after 8 hours] with maximum 20 sustained release levels achieved after 20 hours.

EXAMPLE 4 – Multiparticulate ODV Succinate (DVS) Formulation

Ingredient	mg/tablet
DVS-233	303.5
Microcrystalline cellulose	231.35
povidone	25

Controlled Release Coat	
Ethylcellulose dispersion, NF (15% solids)	85
Water*	NA
Enteric Coat	
Eudragit L30D-55 Dispersion (30% solids)	56
Triethyl citrate	6
Sodium hydroxide	9
talc	30
Water*	NA

* Does not appear in final product

The present invention is not to be limited in scope by the specific
embodiments described herein. Various modifications to these embodiments will be
5 obvious to one of skill in the art from the description. Such modifications fall within
the scope of the appended claims.

Patents, patent applications, publications, procedures and the like are cited
throughout the application. The disclosures of these documents are incorporated by
reference herein in their entireties. To the extent that a conflict may exist between the
10 specification and a reference, the language of the disclosure made herein controls.

What is Claimed is:

1. A multiparticulate formulation of an O-desmethylvenlafaxine (ODV) comprising a multiparticulate form of ODV succinate and/or ODV formate.
2. The formulation according to claim 1, wherein said multiparticulate formulation is a sustained release formulation or a delayed release formulation.
3. The formulation according to claim 1 or claim 2, wherein said formulation comprises spheroids, beads or pellets of an ODV.
4. The formulation according to claim 3, wherein the pellets are about 0.6 mm to about 1 mm in size.
5. The formulation according to any one of claims 1 to 4, wherein the multiparticulate further comprises rate controlling polymers.
6. The formulation according to claim 5, wherein the rate controlling polymers are selected from the group consisting of hydrophilic polymers and inert plasticized polymers.
7. The formulation according to claim 1, wherein the multiparticulates further comprise a diluent, filler, glidant, antiadherent, and/or an adjuvant.
8. The formulation according to any one of claims 1 to 7, wherein the multiparticulates comprise a film coating.
9. A method for treating depression in a subject in need thereof, comprising administering to the patient a composition comprising a multiparticulate formulation of an ODV succinate or formate according to any of claims 1-8.

10. A method for reducing the gastrointestinal side-effects of venlafaxine in a subject undergoing treatment therewith comprising administering to the patient a composition comprising a multiparticulate formulation of an ODV according to any of claims 1-8.

11. A modified release formulation of a multiparticulate comprising about 3 % w/w to about 70% w/w O-desmethylvenlafaxine succinate or formate and about 5% w/w to about 75% w/w microcrystalline cellulose.

12. The modified release formulation according to claim 11, wherein the multiparticulate further comprises a seal coat.

13. The modified release formulation according to claim 12, wherein the seal coat comprises hydroxypropyl methylcellulose.

14. The modified release formulation according to any of claims 11-13, wherein the multiparticulate further comprises an enteric coat selected from among polymethylacrylates, hypomellose, ethylcellulose and combinations thereof.

15. The modified release formulation according to claim 14, wherein the enteric coat comprises ethylcellulose.

16. A method for treating depression in a subject in need thereof, comprising administering to the patient a modified formulation according to any one of claims 11-15.

17. A method for reducing the gastrointestinal side-effects of an ODV in a subject undergoing treatment therewith comprising administering to the patient a modified formulation according to any of claims 11-15.

18. A modified release venlafaxine product comprising 10 mg to 400 mg of multiparticulate O-desmethylvenlafaxine (ODV) succinate or formate.
19. The product according to claim 18 that is a capsule shell containing said multiparticulate ODV succinate or formate.
20. The product according to claim 18 that is a compressed tablet comprising said multiparticulate ODV succinate or formate.
21. A method for treating depression in a subject in need thereof, comprising administering to the patient a regimen comprising a product according to claim 18.
22. A method for reducing the gastrointestinal side-effects associated with venlafaxine treatment, said method comprising administering to the patient a regimen comprising a product according to any one of claims 18 to 20.
23. A method for delivering ODV to a pediatric or geriatric patient, said method comprising the step of administering pellets, beads or spheroids according to claim 3 or claim 4.
24. A product comprising multiparticulate ODV succinate and/or formate.
25. The product according to claim 24 which comprises a foil packet comprising the multiparticulate ODV succinate and/or formate.
26. A multiparticulate formulation of ODV formate or succinate that can be administered for patients through naso-gastric tubes, as a suspension or dispersed over semi-solid foods.
27. A delayed release multiparticulate formulation of ODV formate or succinate for treatment of irritable bowel syndrome.

28. Use of a formulation according to any of claims 1-8, 11-15, and 26-27 in preparing a medicament.

29. Use according to claim 28, wherein said medicament is useful in the treatment of depression, gastrointestinal side-effects of venlafaxine in a subject undergoing treatment therewith, and irritable bowel syndrome.

30. Use of a formulation according to claims 3 or 4 in the preparation of a medicament for delivery to a pediatric or geriatric patient.

31. Use of a formulation according to any of claims 1-8, 11-15, and 26-27 in preparing a dosing unit.

32. Use according to claim 31, wherein said dosing unit is for oral, transdermal, or mucosal administration.

33. A pharmaceutical pack comprising a container having a formulation according to any of claims 1-8, 11-15, and 26-27 in unit dosage form.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/002215

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/16 A61K9/22 A61K9/52 A61K31/135 A61K31/137
A61P25/24 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/064543 A (WYETH) 22 August 2002 (2002-08-22) cited in the application	1-33
Y	the whole document	1-22, 24-29, 31-33
X	----- WO 03/103603 A (WYETH; HADFIELD, ANTHONY, FRANCIS; WINKLEY, MICHAEL, WILLIAM) 18 December 2003 (2003-12-18)	1-33
Y	the whole document	1-22, 24-29, 31-33
	----- -/--	

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

<p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p>	<p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p>
--	--

Date of the actual completion of the international search 9 June 2005	Date of mailing of the international search report 21/06/2005
---	---

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Minas, S
--	---

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/002215

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 00/76955 A (AMERICAN HOME PRODUCTS CORPORATION) 21 December 2000 (2000-12-21)</p> <p>page 17, paragraph 2; claims 5,6; example 1 page 17, last paragraph the whole document</p> <p>-----</p>	<p>1-17, 24-29, 31-33</p>
P,X	<p>EP 1 481 690 A (ROHM AND HAAS COMPANY) 1 December 2004 (2004-12-01)</p> <p>page 5, column 7, last line , paragraph 31 - column 8, line 40, paragraph 33</p> <p>-----</p>	<p>1-3,5,9, 10,18, 21,22, 24,25, 28-33</p>
Y	<p>US 6 342 533 B1 (JERUSSI THOMAS P ET AL) 29 January 2002 (2002-01-29) claims; tables II,III</p> <p>-----</p>	<p>18-22</p>
Y	<p>WO 00/32555 A (SEPRACOR INC) 8 June 2000 (2000-06-08) cited in the application claims; tables II,III</p> <p>-----</p>	<p>18-22</p>
Y	<p>WO 00/59851 A (SEPRACOR INC) 12 October 2000 (2000-10-12) claims 1-16</p> <p>-----</p>	<p>18-22</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/002215

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9,10,16,17 and 21-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2005/002215

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02064543	A	22-08-2002	BR 0207157 A 17-02-2004
			CA 2436668 A1 22-08-2002
			CN 1501909 A 02-06-2004
			EP 1360169 A2 12-11-2003
			HU 0303128 A2 29-12-2003
			JP 2004529877 T 30-09-2004
			MX PA03007043 A 18-11-2003
			NO 20033538 A 11-08-2003
			PL 364605 A1 13-12-2004
			WO 02064543 A2 22-08-2002
			US 2003045583 A1 06-03-2003
			US 2004044241 A1 04-03-2004
			US 2005096479 A1 05-05-2005
			ZA 200307116 A 13-12-2004

WO 03103603	A	18-12-2003	AU 2003247515 A1 22-12-2003
			BR 0311693 A 22-03-2005
			CA 2488613 A1 18-12-2003
			EP 1519720 A2 06-04-2005
			WO 03103603 A2 18-12-2003
			US 2003236309 A1 25-12-2003

WO 0076955	A	21-12-2000	AU 5738700 A 02-01-2001
			WO 0076955 A1 21-12-2000

EP 1481690	A	01-12-2004	CN 1572326 A 02-02-2005
			EP 1481690 A1 01-12-2004
			JP 2004359665 A 24-12-2004
			US 2004241135 A1 02-12-2004

US 6342533	B1	29-01-2002	AU 774408 B2 24-06-2004
			AU 2474900 A 19-06-2000
			CA 2352324 A1 08-06-2000
			EP 1135359 A1 26-09-2001
			JP 2003524613 T 19-08-2003
			US 2002086904 A1 04-07-2002
			WO 0032556 A1 08-06-2000
			US 2003018083 A1 23-01-2003
			US 2004180952 A1 16-09-2004

WO 0032555	A	08-06-2000	US 6197828 B1 06-03-2001
			AU 3106200 A 19-06-2000
			CA 2352321 A1 08-06-2000
			EP 1135358 A1 26-09-2001
			JP 2003501344 T 14-01-2003
			WO 0032555 A1 08-06-2000

WO 0059851	A	12-10-2000	AU 4062700 A 23-10-2000
			CA 2368083 A1 12-10-2000
			CZ 20013607 A3 12-06-2002
			EP 1165487 A1 02-01-2002
			EP 1466889 A1 13-10-2004
			HU 0200898 A2 28-10-2002
			JP 2003521470 T 15-07-2003
			NO 20014816 A 04-12-2001
			NZ 514612 A 30-01-2004
			PL 350924 A1 10-02-2003
			WO 0059851 A1 12-10-2000

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/US2005/002215

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0059851	A	US 2004106576 A1	03-06-2004